301 related articles for article (PubMed ID: 7790860)
1. Biochemistry of somatodendritic dopamine release in substantia nigra: an in vivo comparison with striatal dopamine release.
Heeringa MJ; Abercrombie ED
J Neurochem; 1995 Jul; 65(1):192-200. PubMed ID: 7790860
[TBL] [Abstract][Full Text] [Related]
2. 3-Methoxytyramine formation following monoamine oxidase inhibition is a poor index of dendritic dopamine release in the substantia nigra.
Elverfors A; Pileblad E; Lagerkvist S; Bergquist F; Jonason J; Nissbrandt H
J Neurochem; 1997 Oct; 69(4):1684-92. PubMed ID: 9326297
[TBL] [Abstract][Full Text] [Related]
3. Differential regulation of somatodendritic and nerve terminal dopamine release by serotonergic innervation of substantia nigra.
Cobb WS; Abercrombie ED
J Neurochem; 2003 Feb; 84(3):576-84. PubMed ID: 12558977
[TBL] [Abstract][Full Text] [Related]
4. Biochemistry of somatodendritic dopamine release in substantia nigra: an in vivo comparison with striatal dopamine release.
Abercrombie ED; DeBoer P; Heeringa MJ
Adv Pharmacol; 1998; 42():133-6. PubMed ID: 9327864
[No Abstract] [Full Text] [Related]
5. Relative involvement of globus pallidus and subthalamic nucleus in the regulation of somatodendritic dopamine release in substantia nigra is dopamine-dependent.
Cobb WS; Abercrombie ED
Neuroscience; 2003; 119(3):777-86. PubMed ID: 12809698
[TBL] [Abstract][Full Text] [Related]
6. Modulation of methylenedioxymethamphetamine-induced striatal dopamine release by the interaction between serotonin and gamma-aminobutyric acid in the substantia nigra.
Yamamoto BK; Nash JF; Gudelsky GA
J Pharmacol Exp Ther; 1995 Jun; 273(3):1063-70. PubMed ID: 7791076
[TBL] [Abstract][Full Text] [Related]
7. Microdialysis study of the effects of the antiparkinsonian drug budipine on L-DOPA-induced release of dopamine and 5-hydroxytryptamine by rat substantia nigra and corpus striatum.
Biggs CS; Starr MS
Synapse; 1999 Oct; 34(1):36-46. PubMed ID: 10459170
[TBL] [Abstract][Full Text] [Related]
8. Muscarinic antagonists in substantia nigra influence the decarboxylation of L-dopa in striatum.
Izurieta-Sánchez P; Sarre S; Ebinger G; Michotte Y
Eur J Pharmacol; 2000 Jul; 399(2-3):151-60. PubMed ID: 10884514
[TBL] [Abstract][Full Text] [Related]
9. Novel Ca2+ dependence and time course of somatodendritic dopamine release: substantia nigra versus striatum.
Chen BT; Rice ME
J Neurosci; 2001 Oct; 21(19):7841-7. PubMed ID: 11567075
[TBL] [Abstract][Full Text] [Related]
10. Cholinergic stimulation of rostral and caudal substantia nigra pars compacta produces opposite effects on circling behavior and striatal dopamine release measured by brain microdialysis.
Hernández-López S; Góngora-Alfaro JL; Martínez-Fong D; Rosales MG; Aceves J
Neuroscience; 1994 Sep; 62(2):441-7. PubMed ID: 7830890
[TBL] [Abstract][Full Text] [Related]
11. GABA(A) receptors in the pars compacta and GABA(B) receptors in the pars reticulata of rat substantia nigra modulate the striatal dopamine release.
Balon N; Kriem B; Weiss M; Rostain JC
Neurochem Res; 2002 May; 27(5):373-9. PubMed ID: 12064352
[TBL] [Abstract][Full Text] [Related]
12. Reserpine-insensitive dopamine release in the substantia nigra?
Elverfors A; Nissbrandt H
Brain Res; 1991 Aug; 557(1-2):5-12. PubMed ID: 1720998
[TBL] [Abstract][Full Text] [Related]
13. Relationship between asymmetries in striatal dopamine release and the direction of amphetamine-induced rotation during the first week following a unilateral 6-OHDA lesion of the substantia nigra.
Robinson TE; Noordhoorn M; Chan EM; Mocsary Z; Camp DM; Whishaw IQ
Synapse; 1994 May; 17(1):16-25. PubMed ID: 8042143
[TBL] [Abstract][Full Text] [Related]
14. Substance P and neurokinin A regulate by different mechanisms dopamine release from dendrites and nerve terminals of the nigrostriatal dopaminergic neurons.
Baruch P; Artaud F; Godeheu G; Barbeito L; Glowinski J; Chéramy A
Neuroscience; 1988 Jun; 25(3):889-98. PubMed ID: 2457187
[TBL] [Abstract][Full Text] [Related]
15. Biotransformation of L-DOPA to dopamine in the substantia nigra of freely moving rats: effect of dopamine receptor agonists and antagonists.
Sarre S; Vandeneede D; Ebinger G; Michotte Y
J Neurochem; 1998 Apr; 70(4):1730-9. PubMed ID: 9523592
[TBL] [Abstract][Full Text] [Related]
16. Reserpine pretreatment prevents increases in extracellular striatal dopamine following L-DOPA administration in rats with nigrostriatal denervation.
Kannari K; Tanaka H; Maeda T; Tomiyama M; Suda T; Matsunaga M
J Neurochem; 2000 Jan; 74(1):263-9. PubMed ID: 10617128
[TBL] [Abstract][Full Text] [Related]
17. Influence of monoamine oxidase inhibition on the release of 3H-dopamine elicited by potassium and by amphetamine from the rat substantia nigra and corpus striatum.
Arbilla S; Langer SZ
Naunyn Schmiedebergs Arch Pharmacol; 1980 Feb; 311(1):45-52. PubMed ID: 7366741
[No Abstract] [Full Text] [Related]
18. Striatal serotonin 2C receptors decrease nigrostriatal dopamine release by increasing GABA-A receptor tone in the substantia nigra.
Burke MV; Nocjar C; Sonneborn AJ; McCreary AC; Pehek EA
J Neurochem; 2014 Nov; 131(4):432-43. PubMed ID: 25073477
[TBL] [Abstract][Full Text] [Related]
19. 17β-Estradiol infusions into the dorsal striatum rapidly increase dorsal striatal dopamine release in vivo.
Shams WM; Sanio C; Quinlan MG; Brake WG
Neuroscience; 2016 Aug; 330():162-70. PubMed ID: 27256507
[TBL] [Abstract][Full Text] [Related]
20. Partial depletion of dopamine in substantia nigra impairs motor performance without altering striatal dopamine neurotransmission.
Andersson DR; Nissbrandt H; Bergquist F
Eur J Neurosci; 2006 Jul; 24(2):617-24. PubMed ID: 16903863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
